Published in Diabetes on September 10, 2012
Zinc transporter 8 (ZnT8) autoantibody epitope specificity and affinity examined with recombinant ZnT8 variant proteins in specific ZnT8R and ZnT8W autoantibody-positive type 1 diabetes patients. Clin Exp Immunol (2015) 0.76
Novel prokaryotic expression of thioredoxin-fused insulinoma associated protein tyrosine phosphatase 2 (IA-2), its characterization and immunodiagnostic application. BMC Biotechnol (2016) 0.75
Redox redux: revisiting PTPs and the control of cell signaling. Cell (2005) 5.10
Prediction of type I diabetes in first-degree relatives using a combination of insulin, GAD, and ICA512bdc/IA-2 autoantibodies. Diabetes (1996) 4.20
Large-scale structural analysis of the classical human protein tyrosine phosphatome. Cell (2009) 3.51
Harmonization of glutamic acid decarboxylase and islet antigen-2 autoantibody assays for national institute of diabetes and digestive and kidney diseases consortia. J Clin Endocrinol Metab (2010) 2.70
Prediction of IDDM in the general population: strategies based on combinations of autoantibody markers. Diabetes (1997) 2.65
Mature high-affinity immune responses to (pro)insulin anticipate the autoimmune cascade that leads to type 1 diabetes. J Clin Invest (2004) 2.34
Molecular cloning and identification of a receptor-type protein tyrosine phosphatase, IA-2, from human insulinoma. DNA Cell Biol (1994) 2.13
Combined analysis of autoantibodies improves prediction of IDDM in islet cell antibody-positive relatives. Diabetes (1994) 1.82
Islet cell antigen 512 is a diabetes-specific islet autoantigen related to protein tyrosine phosphatases. J Immunol (1994) 1.77
Relationship of the 37,000- and 40,000-M(r) tryptic fragments of islet antigens in insulin-dependent diabetes to the protein tyrosine phosphatase-like molecule IA-2 (ICA512). J Clin Invest (1995) 1.60
ICA 512, an autoantigen of type I diabetes, is an intrinsic membrane protein of neurosecretory granules. EMBO J (1996) 1.59
Identification of protein tyrosine phosphatase-like IA2 (islet cell antigen 512) as the insulin-dependent diabetes-related 37/40K autoantigen and a target of islet-cell antibodies. J Immunol (1995) 1.53
Identification of a second transmembrane protein tyrosine phosphatase, IA-2beta, as an autoantigen in insulin-dependent diabetes mellitus: precursor of the 37-kDa tryptic fragment. Proc Natl Acad Sci U S A (1996) 1.51
Structural genomics of protein phosphatases. J Struct Funct Genomics (2007) 1.40
Reversible oxidation of the membrane distal domain of receptor PTPalpha is mediated by a cyclic sulfenamide. Biochemistry (2007) 1.26
Early development and spreading of autoantibodies to epitopes of IA-2 and their association with progression to type 1 diabetes. J Immunol (1998) 1.19
Identification of the 37-kDa antigen in IDDM as a tyrosine phosphatase-like protein (phogrin) related to IA-2. Diabetes (1996) 1.17
IA-2 (islet cell antigen 512) is the primary target of humoral autoimmunity against type 1 diabetes-associated tyrosine phosphatase autoantigens. J Immunol (1998) 1.12
Rising incidence of type 1 diabetes is associated with altered immunophenotype at diagnosis. Diabetes (2012) 1.11
Autoantibodies in insulin-dependent diabetes recognize distinct cytoplasmic domains of the protein tyrosine phosphatase-like IA-2 autoantigen. J Immunol (1996) 1.03
Autoantibodies to IA-2 and IA-2 beta in insulin-dependent diabetes mellitus recognize conformational epitopes: location of the 37- and 40-kDa fragments determined. J Immunol (1997) 1.02
Combined positivity for HLA DQ2/DQ8 and IA-2 antibodies defines population at high risk of developing type 1 diabetes. Diabetologia (2005) 1.00
Definition of multiple ICA512/phogrin autoantibody epitopes and detection of intramolecular epitope spreading in relatives of patients with type 1 diabetes. Diabetes (1998) 0.94
Azide and Tween-20 reduce binding to autoantibody epitopes of islet antigen-2; implications for assay performance and reproducibility. J Immunol Methods (2009) 0.91
Singlet oxygen inactivates protein tyrosine phosphatase-1B by oxidation of the active site cysteine. Biol Chem (2006) 0.87
Autoantibodies to IA-2 in IDDM: location of major antigenic determinants. Diabetes (1997) 0.87
Autoantibodies and associated T-cell responses to determinants within the 831-860 region of the autoantigen IA-2 in Type 1 diabetes. J Autoimmun (2009) 0.86
Comparison of IA-2 with IA-2beta and with six other members of the protein tyrosine phosphatase family: recognition of antigenic determinants by IDDM sera. J Autoimmun (1997) 0.85
Mapping of epitopes for autoantibodies to the type 1 diabetes autoantigen IA-2 by peptide phage display and molecular modeling: overlap of antibody and T cell determinants. J Immunol (2004) 0.85
Cross reactivity between IA-2 and phogrin/IA-2beta in binding of autoantibodies in IDDM. Diabetologia (1997) 0.84
Crystal structure of the major diabetes autoantigen insulinoma-associated protein 2 reveals distinctive immune epitopes. Diabetes (2007) 0.82
Monoclonal antibody 76F distinguishes IA-2 from IA-2beta and overlaps an autoantibody epitope. J Autoimmun (2006) 0.81
Human monoclonal antibodies isolated from type I diabetes patients define multiple epitopes in the protein tyrosine phosphatase-like IA-2 antigen. J Immunol (2000) 0.78
High-yield expression of properly folded insulinoma-associated protein intracellular domain (IA-2ic) in Escherichia coli. Biotechnol Appl Biochem (2003) 0.78
Mapping of novel autoreactive epitopes of the diabetes-associated autoantigen IA-2. Clin Exp Immunol (2000) 0.77
Fine mapping of diabetes-associated IA-2 specific autoantibodies. J Autoimmun (2003) 0.77
ICA512(IA-2) epitope specific assays distinguish transient from diabetes associated autoantibodies. J Autoimmun (2002) 0.77
Association between IA-2 autoantibody epitope specificities and age of onset in Japanese patients with autoimmune diabetes. J Autoimmun (2001) 0.77
Risk of pediatric celiac disease according to HLA haplotype and country. N Engl J Med (2014) 5.44
Stratification of type 1 diabetes risk on the basis of islet autoantibody characteristics. Diabetes (2004) 2.74
Harmonization of glutamic acid decarboxylase and islet antigen-2 autoantibody assays for national institute of diabetes and digestive and kidney diseases consortia. J Clin Endocrinol Metab (2010) 2.70
The TrialNet Natural History Study of the Development of Type 1 Diabetes: objectives, design, and initial results. Pediatr Diabetes (2008) 2.60
The rising incidence of childhood type 1 diabetes and reduced contribution of high-risk HLA haplotypes. Lancet (2004) 2.59
Undiagnosed coeliac disease at age seven: population based prospective birth cohort study. BMJ (2004) 2.26
Genome-wide association analysis of autoantibody positivity in type 1 diabetes cases. PLoS Genet (2011) 2.25
Systematic assessment of etiology in adults with a clinical diagnosis of young-onset type 2 diabetes is a successful strategy for identifying maturity-onset diabetes of the young. Diabetes Care (2012) 1.95
Maternal microchimerism in peripheral blood in type 1 diabetes and pancreatic islet beta cell microchimerism. Proc Natl Acad Sci U S A (2007) 1.92
HLA genotyping supports a nonautoimmune etiology in patients diagnosed with diabetes under the age of 6 months. Diabetes (2006) 1.66
Absolute risk of childhood-onset type 1 diabetes defined by human leukocyte antigen class II genotype: a population-based study in the United Kingdom. J Clin Endocrinol Metab (2004) 1.60
Zinc transporter-8 autoantibodies improve prediction of type 1 diabetes in relatives positive for the standard biochemical autoantibodies. Diabetes Care (2012) 1.45
Insulin gene mutations as cause of diabetes in children negative for five type 1 diabetes autoantibodies. Diabetes Care (2008) 1.38
Measurement of islet cell antibodies in the Type 1 Diabetes Genetics Consortium: efforts to harmonize procedures among the laboratories. Clin Trials (2010) 1.33
Evidence that HLA class I and II associations with type 1 diabetes, autoantibodies to GAD and autoantibodies to IA-2, are distinct. Diabetes (2011) 1.20
Diabetes antibody standardization program: first proficiency evaluation of assays for autoantibodies to zinc transporter 8. Clin Chem (2011) 1.17
Combined testing of antibody titer and affinity improves insulin autoantibody measurement: Diabetes Antibody Standardization Program. Clin Immunol (2006) 1.13
Contribution of antibodies against IA-2β and zinc transporter 8 to classification of diabetes diagnosed under 40 years of age. Diabetes Care (2011) 1.12
Rising incidence of type 1 diabetes is associated with altered immunophenotype at diagnosis. Diabetes (2012) 1.11
Delayed exposure to wheat and barley proteins reduces diabetes incidence in non-obese diabetic mice. Clin Immunol (2004) 1.08
High familial risk and genetic susceptibility in early onset childhood diabetes. Diabetes (2002) 1.04
Identifying hepatic nuclear factor 1alpha mutations in children and young adults with a clinical diagnosis of type 1 diabetes. Diabetes Care (2003) 1.03
Non-specific binding to protein A Sepharose and protein G Sepharose in insulin autoantibody assays may be reduced by pre-treatment with glycine or ethanolamine. J Immunol Methods (2006) 1.00
Alloantibody and autoantibody monitoring predicts islet transplantation outcome in human type 1 diabetes. Diabetes (2012) 0.99
Protein 4.2: a complex linker. Blood Cells Mol Dis (2009) 0.99
Association of intercellular adhesion molecule-1 gene with type 1 diabetes. Lancet (2003) 0.95
Humoral responses to islet antigen-2 and zinc transporter 8 are attenuated in patients carrying HLA-A*24 alleles at the onset of type 1 diabetes. Diabetes (2013) 0.94
Anti-BSA antibodies are a major cause of non-specific binding in insulin autoantibody radiobinding assays. J Immunol Methods (2010) 0.93
Azide and Tween-20 reduce binding to autoantibody epitopes of islet antigen-2; implications for assay performance and reproducibility. J Immunol Methods (2009) 0.91
Cloning, sequence and expression of the lactate dehydrogenase gene from the human malaria parasite, Plasmodium vivax. Biotechnol Lett (2004) 0.90
The role of autoantibodies to zinc transporter 8 in prediction of type 1 diabetes in relatives: lessons from the European Nicotinamide Diabetes Intervention Trial (ENDIT) cohort. J Clin Endocrinol Metab (2011) 0.89
Predicting type 1 diabetes using autoantibodies: the latest results from the diabetes autoantibody standardization program. Diabetes Technol Ther (2002) 0.86
Islet autoimmunity in children with Down's syndrome. Diabetes (2006) 0.85
Influenza A viruses grow in human pancreatic cells and cause pancreatitis and diabetes in an animal model. J Virol (2012) 0.84
Humoral autoimmune responses to glutamic acid decarboxylase have similar target epitopes and subclass that show titer-dependent disease association. Clin Immunol (2005) 0.83
Is puberty an accelerator of type 1 diabetes in IL6-174CC females? Diabetes (2005) 0.82
Monoclonal antibody 76F distinguishes IA-2 from IA-2beta and overlaps an autoantibody epitope. J Autoimmun (2006) 0.81
Islet autoantibody testing: an end to the trials and tribulations? Diabetes (2013) 0.81
Diabetes Antibody Standardization Program: First evaluation of assays for autoantibodies to IA-2β. Diabetes Care (2011) 0.80
Validation of autoantibody assays in type 1 diabetes: workshop programme. Autoimmunity (2004) 0.80
Zinc transporter 8 autoantibodies increase the predictive value of islet autoantibodies for function loss of technically successful solitary pancreas transplant. Transplantation (2011) 0.79
Cerebellar ataxia, peripheral neuropathy, "gluten sensitivity" and anti-neuronal autoantibodies. Clin Lab (2006) 0.78
Treatment of thyroid-associated orbitopathy with rituximab--a novel therapy for an old disease: case report and literature review. Endocr Pract (2010) 0.78
Fine mapping of diabetes-associated IA-2 specific autoantibodies. J Autoimmun (2003) 0.77
Early-onset, coexisting autoimmunity and decreased HLA-mediated susceptibility are the characteristics of diabetes in Down syndrome. Diabetes Care (2012) 0.76
Proteomic identification of aldolase A as an autoantibody target in patients with atypical movement disorders. Neurol Sci (2012) 0.76
IGF-secreting tumour treated with a combination of growth hormone and glucocorticoids. Clin Endocrinol (Oxf) (2006) 0.76
Early onset of diabetes in the proband is the major determinant of risk in HLA DR3-DQ2/DR4-DQ8 siblings. Diabetes (2013) 0.76
Erratum. Blood and Islet Phenotypes Indicate Immunological Heterogeneity in Type 1 Diabetes. Diabetes 2014;63:3835-3845. Diabetes (2015) 0.75